✦ LIBER ✦

2.445 A summary of the in vitro pharmacology of pardoprunox (SLV308): A novel dopamine D2/D3 partial agonist and 5-HT1A agonist for the treatment of Parkinson's disease

✍ Scribed by A. McCreary; J. Glennon; J.-H. Reinders; M. Hesselink; G. van Scharrenburg

Book ID: 117753005
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 63 KB
Volume: 13
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(08)70765-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P2.104 Effects of pardoprunox (SLV308),

P2.104 Effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity

✍ C. Bétry; A. Etievant; L. Lambas-Senas; A. McCreary; N. Haddjeri 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Double-blind study of pardoprunox, a new

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

✍ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o

Dopamine agonists used in the treatment

Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum

✍ Jacques De Keyser; Jean-Paul De Backer; Nadine Wilczak; Luc Herroelen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 539 KB

P.3.d.007 F15063, a novel antipsychotic

P.3.d.007 F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III. Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents

✍ M.B. Assié; L. Bardin; A.L. Auclair; N. Consul-Denjean; F. Sautel; M.S. Kleven; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Agonist and antagonist actions of yohimb

Agonist and antagonist actions of yohimbine as compared to fluparoxan at α2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states

✍ Mark J. Millan; Adrian Newman-Tancredi; Valérie Audinot; Didier Cussac; François 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 1 views

Herein, we evaluate the interaction of the ␣ 2 -AR antagonist, yohimbine, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freelymoving rats. Yohimbine displays marked affinity at hum

Intrinsic Efficacy of Antipsychotics at

Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist

✍ Burstein, E. S. 📂 Article 📅 2005 🏛 American Society for Pharmacology and Experimental 🌐 English ⚖ 576 KB